Led by a team of African researchers, first doses of the novel T cell-inducing GRAdHIVNE1 vaccine candidate have been given.

H-D Feminine Health, announces it has initiated the first randomized, placebo-controlled, double-blinded Phase 3 clinical trial cleared to proceed by the U.S. Food and Drug Administration (FDA) to ...

Private equity house LDC has backed the expansion plans of a North West-headquartered business which is the UK’s largest site ...

Cedars-Sinai physician-scientists joined peers from around the world at the Alzheimer's Association International Conference ...

Jon Walsh, founder, chief scientific officer, Unlearn, explains how AI-designed therapies and digital twin technology are ...

Clinical trial updates in cancer care include a remote study in small cell lung cancer and new findings in ovarian, solid ...

Phase 1 study results published in Nature Medicine looks at a vaccine for patients with pancreatic and colorectal cancer. Dr Magnus Dillon, Clinician Scientist at The Institute of Cancer Research, ...

The Subject Expert Committee (SEC) under the Central Drugs Standard Control Organisation (CDSCO) has accepted the results of ...

HHS says the elimination of 22 mRNA vaccine development projects for COVID-19 and bird flu signals a shift in vaccine ...

A new vaccine aimed at a common cancer gene mutation could help stop aggressive pancreatic cancers from coming back, a small ...

Kyverna reported $211.7 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which the Company ...

As clinical trials become more complex, success depends on early collaboration, thoughtful protocol design, and practical ...